Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Trial Profile

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacutamab (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Anaplastic large cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TELLOMAK
  • Sponsors Innate Pharma
  • Most Recent Events

    • 17 Oct 2019 According to an Innate Pharma media release, the company expects to use the net proceeds from the Global Offering to advance the Phase II clinical development of IPH4102 through the first activity data for patients with Sezary syndrome, MF and PTCL.
    • 22 Jun 2019 Trial design presented at the 15th International Conference on Malignant Lymphoma (ICML 2019).
    • 19 Jun 2019 According to an Innate Pharma media release, the company will host a key opinion leader (KOL) call focused on the topic of this clinical trial design and rationale in T-cell lymphoma on 20th Jun 2019.The call will feature a presentation by Dr. Pierluigi Porcu, MD, key opinion leader and Principal Investigator of this study.He will discuss the cutaneous T-cell lymphoma (CTCL) and PTCL treatment landscapes and rationale of this trial design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top